Staffing company Robert Half reported better-than-expected earnings, indicating improving demand for staffing services even as overall hiring remains sluggish. The firm also benefits from growth in compliance consulting, providing an additional revenue stream. This suggests Robert Half is navigating the challenging job market effectively, potentially positioning it well for future growth as hiring conditions improve.
The staffing firm Robert Half is noted here with Pluang's Industrials sector data as context for readers. Of 135 priced Industrials-sector US stocks tradable on Pluang, 39 rose and 95 fell today. Notable movers include Delta Air Lines at USD 76.39 with a 1-day change of -3.62% and 100% buy order activity, Booz Allen Hamilton at USD 75.95 down 3.33%, and Nordic American Tankers up 3.32% at USD 7.79. This snapshot is as of Oct 23, 2026 22:21 WIB.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
